Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial Intravascular ultrasound with iMap: the OCTIVUS trial*

Mikkel Hougaard, Henrik Steen Hansen, Per Thayssen, Lisbeth Antonsen, Anders Junker, Karsten Veien, Lisette Okkels Jensen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Background: The aim of this study was to examine the influence of ezetimibe in addition to atorvastatin on plaque composition in patients with first-time ST-segment Elevation Myocardial Infarction treated with primary percutaneous intervention. Methods: Eighty-seven patients were randomized ( 1: 1) to ezetimibe 10mg or placebo in addition to Atorvastatin 80 mg. Intravascular ultrasound with iMap was performed at baseline and after 12 months in a non-infarctrelated artery. Primary endpoint was change in necrotic core (NC). Secondary endpoints were total atheroma volume (TAV) and percentage atheroma volume (PAV). Results: NC did not change significantly: ezetimibe group 24.9 ( 11.9, 51.3) mm(3) to 24.9 ( 15.3, 54.5) mm(3), p = 0.76, placebo group 29.4 ( 16.3, 78.5) mm(3) to 32.0 ( 16.0, 88.7) mm(3), p = 0.30, ( p = 0.35 between groups). TAV was reduced in the ezetimibe group only: ezetimibe ( 200.0 (135.6, 311.9) mm(3) to 189.3 ( 126.4, 269.1) mm(3), p <0.001) compared to placebo group ( 218.4 ( 163.5, 307.9) mm(3) to 212.2 ( 149.9, 394.8) mm(3), p = 0.07) ( p = 0.56 between groups). PAV was reduced in the ezetimibe group only ( 40.1 +/- 8.6% to 39.2 +/- 9.0 p = 0.036) compared to placebo group ( 43.3 +/- 9.4% to 42.2 +/- 10.7 p - 0.07),p - 0.91 between groups. Conclusions: Ezetimibe in addition to atorvastatin therapy did not influence NC content, but was associated with regression of coronary atherosclerosis. (C) 2016 Elsevier Inc. All rights reserved.
OriginalsprogEngelsk
TidsskriftCardiovascular Revascularization Medicine
Vol/bind18
Udgave nummer2
Sider (fra-til)110-117
ISSN1553-8389
DOI
StatusUdgivet - 2017

Fingeraftryk

Fluspirilene
Atherosclerotic Plaques
Placebos
Atorvastatin Calcium
ST Elevation Myocardial Infarction
Coronary Artery Disease

Emneord

  • Atorvastatin
  • Ezetimibe
  • IVUS
  • iMap

Citer dette

@article{3120ec252f67450198d89bd8da0c9785,
title = "Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial Intravascular ultrasound with iMap: the OCTIVUS trial*",
abstract = "Background: The aim of this study was to examine the influence of ezetimibe in addition to atorvastatin on plaque composition in patients with first-time ST-segment Elevation Myocardial Infarction treated with primary percutaneous intervention. Methods: Eighty-seven patients were randomized ( 1: 1) to ezetimibe 10mg or placebo in addition to Atorvastatin 80 mg. Intravascular ultrasound with iMap was performed at baseline and after 12 months in a non-infarctrelated artery. Primary endpoint was change in necrotic core (NC). Secondary endpoints were total atheroma volume (TAV) and percentage atheroma volume (PAV). Results: NC did not change significantly: ezetimibe group 24.9 ( 11.9, 51.3) mm(3) to 24.9 ( 15.3, 54.5) mm(3), p = 0.76, placebo group 29.4 ( 16.3, 78.5) mm(3) to 32.0 ( 16.0, 88.7) mm(3), p = 0.30, ( p = 0.35 between groups). TAV was reduced in the ezetimibe group only: ezetimibe ( 200.0 (135.6, 311.9) mm(3) to 189.3 ( 126.4, 269.1) mm(3), p <0.001) compared to placebo group ( 218.4 ( 163.5, 307.9) mm(3) to 212.2 ( 149.9, 394.8) mm(3), p = 0.07) ( p = 0.56 between groups). PAV was reduced in the ezetimibe group only ( 40.1 +/- 8.6{\%} to 39.2 +/- 9.0 p = 0.036) compared to placebo group ( 43.3 +/- 9.4{\%} to 42.2 +/- 10.7 p - 0.07),p - 0.91 between groups. Conclusions: Ezetimibe in addition to atorvastatin therapy did not influence NC content, but was associated with regression of coronary atherosclerosis. (C) 2016 Elsevier Inc. All rights reserved.",
keywords = "Atorvastatin, Ezetimibe, IVUS, iMap",
author = "Mikkel Hougaard and Hansen, {Henrik Steen} and Per Thayssen and Lisbeth Antonsen and Anders Junker and Karsten Veien and Jensen, {Lisette Okkels}",
year = "2017",
doi = "10.1016/j.carrev.2016.11.010",
language = "English",
volume = "18",
pages = "110--117",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial Intravascular ultrasound with iMap: the OCTIVUS trial*

AU - Hougaard, Mikkel

AU - Hansen, Henrik Steen

AU - Thayssen, Per

AU - Antonsen, Lisbeth

AU - Junker, Anders

AU - Veien, Karsten

AU - Jensen, Lisette Okkels

PY - 2017

Y1 - 2017

N2 - Background: The aim of this study was to examine the influence of ezetimibe in addition to atorvastatin on plaque composition in patients with first-time ST-segment Elevation Myocardial Infarction treated with primary percutaneous intervention. Methods: Eighty-seven patients were randomized ( 1: 1) to ezetimibe 10mg or placebo in addition to Atorvastatin 80 mg. Intravascular ultrasound with iMap was performed at baseline and after 12 months in a non-infarctrelated artery. Primary endpoint was change in necrotic core (NC). Secondary endpoints were total atheroma volume (TAV) and percentage atheroma volume (PAV). Results: NC did not change significantly: ezetimibe group 24.9 ( 11.9, 51.3) mm(3) to 24.9 ( 15.3, 54.5) mm(3), p = 0.76, placebo group 29.4 ( 16.3, 78.5) mm(3) to 32.0 ( 16.0, 88.7) mm(3), p = 0.30, ( p = 0.35 between groups). TAV was reduced in the ezetimibe group only: ezetimibe ( 200.0 (135.6, 311.9) mm(3) to 189.3 ( 126.4, 269.1) mm(3), p <0.001) compared to placebo group ( 218.4 ( 163.5, 307.9) mm(3) to 212.2 ( 149.9, 394.8) mm(3), p = 0.07) ( p = 0.56 between groups). PAV was reduced in the ezetimibe group only ( 40.1 +/- 8.6% to 39.2 +/- 9.0 p = 0.036) compared to placebo group ( 43.3 +/- 9.4% to 42.2 +/- 10.7 p - 0.07),p - 0.91 between groups. Conclusions: Ezetimibe in addition to atorvastatin therapy did not influence NC content, but was associated with regression of coronary atherosclerosis. (C) 2016 Elsevier Inc. All rights reserved.

AB - Background: The aim of this study was to examine the influence of ezetimibe in addition to atorvastatin on plaque composition in patients with first-time ST-segment Elevation Myocardial Infarction treated with primary percutaneous intervention. Methods: Eighty-seven patients were randomized ( 1: 1) to ezetimibe 10mg or placebo in addition to Atorvastatin 80 mg. Intravascular ultrasound with iMap was performed at baseline and after 12 months in a non-infarctrelated artery. Primary endpoint was change in necrotic core (NC). Secondary endpoints were total atheroma volume (TAV) and percentage atheroma volume (PAV). Results: NC did not change significantly: ezetimibe group 24.9 ( 11.9, 51.3) mm(3) to 24.9 ( 15.3, 54.5) mm(3), p = 0.76, placebo group 29.4 ( 16.3, 78.5) mm(3) to 32.0 ( 16.0, 88.7) mm(3), p = 0.30, ( p = 0.35 between groups). TAV was reduced in the ezetimibe group only: ezetimibe ( 200.0 (135.6, 311.9) mm(3) to 189.3 ( 126.4, 269.1) mm(3), p <0.001) compared to placebo group ( 218.4 ( 163.5, 307.9) mm(3) to 212.2 ( 149.9, 394.8) mm(3), p = 0.07) ( p = 0.56 between groups). PAV was reduced in the ezetimibe group only ( 40.1 +/- 8.6% to 39.2 +/- 9.0 p = 0.036) compared to placebo group ( 43.3 +/- 9.4% to 42.2 +/- 10.7 p - 0.07),p - 0.91 between groups. Conclusions: Ezetimibe in addition to atorvastatin therapy did not influence NC content, but was associated with regression of coronary atherosclerosis. (C) 2016 Elsevier Inc. All rights reserved.

KW - Atorvastatin

KW - Ezetimibe

KW - IVUS

KW - iMap

U2 - 10.1016/j.carrev.2016.11.010

DO - 10.1016/j.carrev.2016.11.010

M3 - Journal article

VL - 18

SP - 110

EP - 117

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

IS - 2

ER -